[go: up one dir, main page]

MXPA02012410A - Metodo para tratar enfermedades cardiovasculares usando rapamicina. - Google Patents

Metodo para tratar enfermedades cardiovasculares usando rapamicina.

Info

Publication number
MXPA02012410A
MXPA02012410A MXPA02012410A MXPA02012410A MXPA02012410A MX PA02012410 A MXPA02012410 A MX PA02012410A MX PA02012410 A MXPA02012410 A MX PA02012410A MX PA02012410 A MXPA02012410 A MX PA02012410A MX PA02012410 A MXPA02012410 A MX PA02012410A
Authority
MX
Mexico
Prior art keywords
cardiovascular disease
treating cardiovascular
mammal
treating
rapamycin
Prior art date
Application number
MXPA02012410A
Other languages
English (en)
Inventor
Neal Ivan Azrolan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22789625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02012410(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA02012410A publication Critical patent/MXPA02012410A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona un metodo de tratamiento o inhibicion de una enfermedad cardiovascular, vascular cerebral o vascular periferica en un mamifero en necesidad del mismo, el cual comprende proporcionar a dicho mamifero una cantidad efectiva de una rapamicina.
MXPA02012410A 2000-06-16 2001-06-14 Metodo para tratar enfermedades cardiovasculares usando rapamicina. MXPA02012410A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21211700P 2000-06-16 2000-06-16
PCT/US2001/019179 WO2001097809A2 (en) 2000-06-16 2001-06-14 Method of treating cardiovascular disease using rapamycin

Publications (1)

Publication Number Publication Date
MXPA02012410A true MXPA02012410A (es) 2003-04-25

Family

ID=22789625

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012410A MXPA02012410A (es) 2000-06-16 2001-06-14 Metodo para tratar enfermedades cardiovasculares usando rapamicina.

Country Status (19)

Country Link
US (1) US20020013335A1 (es)
EP (1) EP1292302A2 (es)
JP (1) JP2003535899A (es)
KR (1) KR20030010710A (es)
CN (1) CN1436076A (es)
AR (1) AR028959A1 (es)
AU (2) AU2001268446B2 (es)
BR (1) BR0111601A (es)
CA (1) CA2412636A1 (es)
CZ (1) CZ20024115A3 (es)
EA (1) EA200300027A1 (es)
HU (1) HUP0301244A3 (es)
IL (1) IL153405A0 (es)
MX (1) MXPA02012410A (es)
NO (1) NO20026008D0 (es)
NZ (1) NZ523114A (es)
PL (1) PL365455A1 (es)
WO (1) WO2001097809A2 (es)
ZA (1) ZA200300418B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2269604T (lt) 2001-02-19 2016-11-10 Novartis Ag Inkstų solidinių navikų gydymas rapamicino dariniu
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
PL216224B1 (pl) 2002-02-01 2014-03-31 Ariad Pharmaceuticals Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
KR101131794B1 (ko) 2002-07-30 2012-03-30 와이어쓰 엘엘씨 Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
NZ538781A (en) * 2002-09-17 2007-11-30 Wyeth Corp Oral formulations
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
AR042938A1 (es) 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
US7728033B2 (en) 2003-05-05 2010-06-01 Clinigene International Private Limited Mycophenolate mofetil in diabetic nephropathy
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
DE102004019845A1 (de) * 2004-03-29 2005-10-20 Krka Tovarna Zdravil D D Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
CN100435755C (zh) * 2004-07-27 2008-11-26 微创医疗器械(上海)有限公司 药物洗脱支架
EP1656941A1 (en) * 2004-11-09 2006-05-17 Clinigene International Private Limited Compositions for the treatment of diabetic nephropathy
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
CN100384416C (zh) * 2006-03-20 2008-04-30 杨军 一种用于治疗心血管疾病的药物组合物
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
WO2015103447A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CN102803189B (zh) 2010-03-15 2016-01-20 埃克森美孚化学专利公司 用于生产醇的方法
CA2926747A1 (en) * 2012-10-12 2014-04-17 Arlan RICHARDSON Use of mtor inhibitors to treat vascular cognitive impairment
US10098871B2 (en) * 2013-03-15 2018-10-16 Leslie B. Gordon Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CN105997940A (zh) * 2016-05-11 2016-10-12 中国人民解放军第三军医大学 炎症微环境响应性纳米药物、其制备方法及应用
CN117224557A (zh) * 2023-11-02 2023-12-15 中国人民解放军空军军医大学 柚皮苷联合雷帕霉素在制备治疗高脂血症的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
RU2184541C2 (ru) * 1997-06-13 2002-07-10 Американ Хоум Продактс Корпорейшн Препараты рапамицина для орального применения
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin

Also Published As

Publication number Publication date
CN1436076A (zh) 2003-08-13
NZ523114A (en) 2004-07-30
JP2003535899A (ja) 2003-12-02
HUP0301244A2 (hu) 2003-08-28
AU6844601A (en) 2002-01-02
CA2412636A1 (en) 2001-12-27
NO20026008L (no) 2002-12-13
KR20030010710A (ko) 2003-02-05
CZ20024115A3 (cs) 2003-06-18
WO2001097809A3 (en) 2002-05-10
AR028959A1 (es) 2003-05-28
EP1292302A2 (en) 2003-03-19
WO2001097809A2 (en) 2001-12-27
EA200300027A1 (ru) 2003-06-26
AU2001268446B2 (en) 2005-08-11
IL153405A0 (en) 2003-07-06
PL365455A1 (en) 2005-01-10
BR0111601A (pt) 2003-07-01
HUP0301244A3 (en) 2005-01-28
US20020013335A1 (en) 2002-01-31
NO20026008D0 (no) 2002-12-13
ZA200300418B (en) 2004-04-15

Similar Documents

Publication Publication Date Title
MXPA02012410A (es) Metodo para tratar enfermedades cardiovasculares usando rapamicina.
CA2416976A1 (en) Treatment of estrogen receptor positive carcinoma with a rapamycin and an antiestrogen
AP2004003026A0 (en) Methods for treating ocular neovascular diseases.
WO2001085093A3 (en) Compounds and methods for modulating cerebral amyloid angiopathy
AU2002325835A1 (en) Treatment method, which promotes the removal of dirt, for the surfaces of textiles and non-textiles
ZA200309792B (en) Method for cashless gaming.
MXPA04001524A (es) 29-enoles de rapamicina.
MXPA04001523A (es) Dialdehidos de rapamicina.
EP1328186A4 (en) METHODS OF TREATING VARIOUS EYES DISEASES
PL364995A1 (en) Method for the treatment or prevention of flavivirus
AU2002366641A1 (en) Methods for inhibiting ocular processes
MXPA03005275A (es) Prevencion de la captacion de conservantes en biomateriales.
WO2003006893A3 (en) Methods of inhibiting amyloid toxicity
EP1465968A4 (en) METHODS OF TREATING DISTILLATE DEODORIZER
MX240745B (es) Proceso de hidroprocesamiento.
ZA200203180B (en) Method for preventing dyskinesias.
MXPA03006607A (es) Metodo combinado para tratar trastornos dependientes de hormonas.
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
MX227439B (es) Proceso de hidroprocesamiento.
EP1450820A4 (en) METHOD OF TREATING AND PREVENTING INFLAMMATORY DISEASES
AP2004003070A0 (en) The method of treating cancer.
EP1419236A4 (en) METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS
ZA200206252B (en) Method and compositions for treating an inflammatory disease.
MXPA03004017A (es) Metodo para el tratamiento de inflamacion.
EP1709974A3 (en) Method of treating cardiovascular disease using rapamycin

Legal Events

Date Code Title Description
FA Abandonment or withdrawal